Product Description
SAGE-421 is an oral, NMDA receptor positive allosteric modulator that Sage plans to study for potential use in neurodevelopmental disorders and cognitive recovery and rehabilitation. (Sourced from: https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-first-quarter-2021-financial-results)
Mechanisms of Action: NMDA Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sage
Company Location: CAMBRIDGE MA 02142
Company CEO: Barry E. Greene
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for SAGE-421](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Mood Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|